Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17052736 | 0.86 | HSD17B10 (0.48) | PTGS2TDP1ALDH1A1HPGDPOLB | |
| SCHEMBL17045878 | 0.80 | MEN1 (0.53) | HDAC1HDAC2TDP1 | |
| SCHEMBL31734065 | 0.80 | MEN1 (0.53) | HDAC1HDAC2TDP1 | |
| SCHEMBL5121171 | 0.80 | ALDH1A1 (0.48) | TDP1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL18922450 | 0.78 | PTGS2 (0.52) | PTGS2HDAC1HDAC2ALDH1A1 | |
| SCHEMBL10839920 | 0.76 | HPGD (0.61) | TDP1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL17052733 | 0.75 | PTGS2 (0.50) | PTGS2ALDH1A1HPGDPOLBHSD17B10 | |
| SCHEMBL6564711 | 0.74 | PTGS2 (0.55) | PTGS2ALDH1A1HPGDPOLBHSD17B10 | |
| SCHEMBL13668910 | 0.72 | MTNR1A (0.61) | PTGS2ALDH1A1POLB | |
| SCHEMBL26083083 | 0.72 | CYP1A2 (0.43) | PTGS2TDP1ALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | PTGS2 1823/4885HDAC1 1/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.